November 22, 2013
Approval for Pediatric Use of Topina®Tablets, an Antiepileptic Agent
Tokyo, Japan, November 22, 2013 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo; 4151 President and CEO: Nobuo Hanai; "Kyowa Hakko Kirin") announced today that it has received approval in Japan for an additional dosage and administration of Topina® Tablets (Generic name: topiramate) for the treatment of partial onset seizures in pediatric epileptic patients aged two years or older as an adjunctive therapy with other antiepileptic drugs.
Since the launch in September 2007, Topina® Tablets have been used in adult epileptic patients for the treatment of partial onset seizures inadequately controlled with other antiepileptic drugs. This approval for pediatric dosage and administration allows Topina® Tablets to be prescribed for epileptic patients two years of age or older. Topina® Tablets will contribute to pharmacotherapy for pediatric epilepsy because of their efficacy and tolerability demonstrated in combination with existing antiepileptic drugs.
Kyowa Hakko Kirin has four strategic categories including the central nervous system (CNS) area, and is endeavoring to contribute to the treatment of epilepsy through the further development of antiepileptic agents and the provision of related information.
About four categories
These are the following four disease areas: Nephrology, Oncology, Immunology&Allergy and Central Nervous System, as presented in Kyowa Hakko Kirin's FY 2013-2015 medium-term business plan.
Kyowa Hakko Kirin